Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Liver International · 2025-04 · 45 (4)
DOI: 10.1111/liv.16117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 12.10.2024. Verfasst von Maria Castanho Martins und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Medicine and Fibrosis Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Lipase, Membrane Proteins, Liver Cirrhosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research University College London Hospitals - Biomedical Research Centre, Austrian Science Fund, Medical Scientific Fund of the Mayor of the City of Vienna.
Abstract (Originalsprache)
Aims
Since its discovery, the patatin‐like phospholipase domain containing 3 (PNPLA3) (rs738409 C>G p.I148M) variant has been studied extensively to unravel its molecular function. Although several studies proved a causal relationship between the PNPLA3 I148M variant and MASLD development and particularly fibrosis, the pathological mechanisms promoting this phenotype have not yet been fully clarified.
Methods
We summarise the latest data regarding the PNPLA3 I148M variant in hepatic stellate cells (HSCs) activation and macrophage biology or the path to inflammation‐induced fibrosis.
Results
Elegant but contradictory studies have ascribed PNPLA3 a hydrolase or an acyltransferase function. The PNPLA3 I148M results in hepatic lipid accumulation, which predisposes the hepatocyte to lipotoxicity and lipo‐apoptosis, producing DAMPs, cytokines and chemokines leading to recruitment and activation of macrophages and HSCs, propagating fibrosis. Recent studies showed that the PNPLA3 I148M variant alters HSCs biology via attenuation of PPARγ, AP‐1, LXRα and TGFβ activity and signalling.
Conclusions
The advent of refined techniques in isolating HSCs has made PNPLA3's direct role in HSCs for liver fibrosis development more apparent. However, many other mechanisms still need detailed investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regenerative Medicine and Fibrosis Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK.
- Hans Popper Laboratory of Molecular Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Maria Castanho Martins, Krista Rombouts
Förderung
- National Institute for Health Research University College London Hospitals - Biomedical Research Centre
- Austrian Science Fund
- Medical Scientific Fund of the Mayor of the City of Vienna
Zitieren
APA
Castanho Martins, M., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2025). Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk. Liver International, 45(4). https://doi.org/10.1111/liv.16117
Vancouver
Castanho Martins M, Dixon ED, Lupo G, Claudel T, Trauner M, Rombouts K. Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk. Liver International. 2025;45(4). doi:10.1111/liv.16117
BibTeX
@article{CastanhoMartins2025,
author = {Castanho Martins, Maria and Dixon, Emmanuel Dauda and Lupo, Giulia and Claudel, Thierry and Trauner, Michael and Rombouts, Krista},
title = {Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk},
journal = {Liver International},
year = {2025},
volume = {45},
number = {4},
doi = {10.1111/liv.16117}
}
EUVIMED